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Abstract  23 
Inflammatory Bowel Disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis, 24 
is characterised by chronic inflammation of the gastrointestinal tract. Aetiology involves a 25 
combination of genetic and environmental factors resulting in abnormal immune responses 26 
to intestinal microbiota.  Genetic studies have strongly linked genes involved in autophagy to 27 
CD, and genes involved in the unfolded protein response (UPR) to IBD. The UPR is triggered 28 
in response to accumulation of misfolded proteins in the endoplasmic reticulum (ER) and 29 
autophagy plays a key role to relieve ER-stress and restore homeostasis. This review 30 
summarises the known interactions between autophagy and the UPR and discusses the 31 
impact of these converging pathways on IBD pathogenesis. With a paucity of effective long-32 
term treatments for IBD, targeting of synergistic pathways may provide novel and more 33 
effective therapeutic options.  34 
Keywords:  IBD, autophagy, unfolded protein response, ER stress. 35 
36 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
Introduction  37 
Inflammatory Bowel Disease (IBD) is a group of inflammatory diseases that includes Crohn’s 38 
disease (CD), ulcerative colitis (UC) and IBD unclassified (IBDU). The incidence rate for IBD is 39 
approximately 50-200 in 100,000 persons per year in Western countries [1] and following 40 
diagnosis the natural history of the condition is characterized by periods of relapse and 41 
remission, with symptoms commonly including abdominal pain, chronic diarrhoea, weight 42 
loss and lethargy [2]. CD is distinguished from UC due to the presence of submucosal or 43 
transmural inflammation and macroscopic changes that often occur in a non-contiguous 44 
pattern anywhere within the digestive tract [1]. UC is localised to the colon and inflammation 45 
is limited to the mucosa and epithelial lining of the gastrointestinal (GI) tract [2]. Patients can 46 
be diagnosed with IBDU when a conclusive distinction between CD and UC cannot be made, 47 
although this may well represent a distinct sub-type. At present there is no cure for IBD and 48 
medications such as corticosteroids, aminosalicylates, immunomodulators and biological 49 
agents are aimed at inducing and maintaining remission of disease by modifying inflammatory 50 
processes [3].  51 
The aetiopathology of IBD is multifactorial in nature, with genetic predisposition, 52 
environmental triggers (e.g. smoking, appendicectomy, diet, pollution, antibiotics and stress) 53 
and a dysregulated mucosal immune response contributing to disease [4]. Examination of the 54 
gut microbiome has revealed that IBD is associated with microbial dysbiosis, including an 55 
expansion of facultative anaerobic bacteria of the family Enterobacteriaceae [5]. Several 56 
potentially causative agents have been identified, most notably Escherichia coli strains with 57 
an adherent and invasive phenotype (AIEC) are associated with ileal mucosa in CD [6]. 58 
Genome wide association studies (GWAS) have identified 240 IBD susceptibility loci to date 59 
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 4 
[7], and have confirmed association with previously recognised susceptibility genes including 60 
Nucleotide-binding oligomerisation domain-containing protein 2 (NOD2). GWAS have also 61 
identified the strong association of CD with genes involved in the autophagy pathway, 62 
including autophagy-related protein (ATG)16L1, Immunity-related GTPase family M protein 63 
(IRGM) and leucine rich repeat kinase 2 (LRRK2) [8].  The strong association of IBD with 64 
endoplasmic reticulum (ER) stress/Unfolded protein response (UPR) genes including x-box-65 
binding protein 1 (XBP1) [9] and genes involved in intestinal barrier function  such as MUC2 66 
[10] and Anterior gradient 2 (AGR2) [11] have been detected by gene targeted approaches. 67 
Together, these genetic studies have led to increased research exploring links between 68 
autophagy and ER stress/UPR dysregulation and IBD pathogenesis. 69 
Autophagy 70 
 71 
Autophagy is an intracellular process that plays an important housekeeping role by degrading 72 
excessive, damaged or aged proteins and organelles to maintain cellular homeostasis [12]. 73 
Basal autophagy is tightly regulated by the coordinated activity of autophagy-related (ATG) 74 
proteins [13] and  constitutes an important survival mechanism induced in response to 75 
multiple stress conditions such as nutrient deprivation, hypoxia, DNA damage or intracellular 76 
pathogens [12]. There are three main types of autophagy in mammalian cells; 77 
macroautophagy (herein referred to as autophagy), microautophagy and chaperone-78 
mediated autophagy [12].  79 
When autophagy is initiated a double membrane vesicle is formed (the autophagosome) 80 
around the cargo to be degraded (Figure 1). The mature autophagosome then fuses with a 81 
lysosome to form an autophagolysosome, in which lysosomal enzymes degrade the inner 82 
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 5 
membrane and cargo and the resulting macromolecules are released into the cytosol for 83 
recycling (Figure 1).  84 
Selective types of autophagy also exist, including autophagy of microorganisms (xenophagy) 85 
and autophagy of the ER membrane (ER-phagy), which use specific receptors and adaptor 86 
proteins to link the cargo to the autophagy machinery [14]. For example, Sequestosome 87 
1/p62-like receptors (SLRs) target cytosolic pathogens and other cargo to initiate autophagy 88 
[15]. SLRs function by binding to the small regulatory protein ubiquitin on the surface of cargo 89 
[16–18] and subsequently associate  with the autophagy machinery via a binding motif called 90 
the LC3-interacting region (LIR) [19]. Adaptor proteins, such as autophagy-linked FYVE protein 91 
(ALFY), can also bind ubiquitinated pathogens via p62 to promote association with the 92 
autophagy machinery [20]. To date, five main types of SLR have been described; 93 
sequestosome 1/p62, optineurin [18], NBR1 (Neighbor of BRCA1 gene 1) [21], NDP52 (Nuclear 94 
Domain 10 Protein 52) [17] and the NDP52-like receptor calcoco3 (Calcium-binding and 95 
coiled-coil domain-containing protein 3) [22], and specific cargo receptors are important for 96 
distinct types of selective autophagy. For example, a recent study has shown that the non-97 
canonical cargo receptor cell-cycle progression gene 1 (CCPG1) is essential for ER-phagy [23], 98 
while another study demonstrated an integral role for optineurin in the maintenance of ER 99 
homeostasis by assisting the removal of hyper-activated UPR kinases [24].  100 
Autophagy and CD 101 
Autophagy affects many essential cellular processes and dysregulation of autophagy has been 102 
linked to a multitude of human diseases [25]. Autophagy plays an important role in both 103 
innate and adaptive immune signalling pathways and loss of immune regulation is a key event 104 
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leading to the chronic inflammation observed in CD [26]. Impaired autophagy responses have 105 
been observed in a range of cell types derived from CD patients including the specialized 106 
intestinal epithelial cells (IECs) Paneth cells and goblet cells, and leukocytes, such as 107 
macrophages and dendritic cells [27].  108 
Functional studies have linked impaired autophagy to CD-associated genetic variants in 109 
NOD2, ATG16L1, IRGM and LRRK2. The single nucleotide polymorphism (SNP) in ATG16L1 110 
causes a single amino acid change from threonine to alanine at position 300 (T300A) [28], 111 
which is associated with Paneth cell and goblet cell dysfunction, and significantly impairs 112 
autophagic clearance of pathogens [29–32]. IRGM is required for the initiation of xenophagy 113 
and the clearance of intracellular organisms such as Mycobacterium tuberculosis [33] and 114 
dysregulation of IRGM expression compromises the control of intracellular replication of CD-115 
associated adherent invasive Escherichia coli (AIEC) by autophagy [34]. LRRK2 expression is 116 
increased in colonic biopsy specimens from patients with CD [35] and functionally LRRK2 can 117 
enhance NFκB-dependent transcription, while small interfering RNA [siRNA] knockdown of 118 
LRRK2 interferes with bacterial killing [35]. 119 
NOD2 is a member of the Nod-like receptor (NLR) family of pattern recognition receptors 120 
(PRR) and recognises a component of the bacterial cell wall muramyl dipeptide (MDP) to 121 
induce innate immune responses [36]. CD-associated NOD2 SNPs (R702W, G908R and 122 
L1007fs) affect the leucine rich repeat domain disrupting interaction with MDP and 123 
abrogating immune responses initiated by this receptor [37]. The immunoregulatory 124 
properties of NOD2 have also been linked to autophagy, and CD susceptibility is heightened 125 
when ATG16L1 and NOD2 variants present in combination, causing synergistic genetic 126 
epistasis [38,39]. A direct functional interaction between these proteins has been 127 
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determined; NOD2 was shown to recruit ATG16L1 to the plasma membrane to initiate 128 
autophagy at the sites of bacterial entry [40], and in a separate study IRGM was shown to 129 
regulate the formation of a complex containing NOD2 and ATG16L1 that is necessary for the 130 
induction of xenophagy [41]. The interaction of IRGM with NOD2 also stimulates 131 
phosphorylation cascades involving AMPK, ULK1 and Beclin1 that regulate autophagy 132 
initiation complexes [41]. Cells harbouring CD-associated NOD2 variants and/or the ATG16L1 133 
T300A variant exhibit a number of disrupted functions linked to autophagy including reduced 134 
production of antimicrobial peptides, enhanced pro-inflammatory responses and aberrant 135 
activation of adaptive immune responses [40,42–44]. 136 
Significantly, abnormalities in the secretory capacity of Paneth cells are observed in mice 137 
deficient for ATG16L1 [30,45,46], NOD2 [47,48], IRGM [49] and LRRK2 [50] indicating that 138 
autophagy plays an essential and specific role in Paneth cell function. Despite the significant 139 
effects on Paneth cell function, mouse strains developed for deficiency in functional ATG16L1 140 
do not exhibit spontaneous intestinal inflammation [29–31]. In contrast, a mouse strain with 141 
targeted deletion of ATG16L1 in IECs developed a spontaneous transmural ileitis similar to 142 
ileal CD [24]. Furthermore, targeted deletion of ATG16L in haematopoietic cells can enhance 143 
susceptibility to DSS-induced acute intestinal injury in mice [51] and ATG16L1 deficiency in 144 
myeloid cells in a mouse strain led to disrupted macrophage function and bacterial clearance 145 
[52]. Murine models with non-functional NOD2 do not develop spontaneous colitis [53], 146 
however a NOD2 mutation similar to the L1007fs mutation increased susceptibility to DSS-147 
induced colitis in mice [54]. Irgm1-deficient mice also exhibit abnormalities in Paneth cells, 148 
accompanied by increased susceptibility to inflammation in the colon and ileum [49]. Finally, 149 
LRRK2 deficiency confers enhanced susceptibility to experimental colitis in mice, which was 150 
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 8 
associated with enhanced nuclear localisation of the transcription factor nuclear factor of 151 
activated T cells (NFAT1), important for regulating innate immune responses [55].  152 
ER-stress and UPR signalling  153 
ER stress results from accumulation of unfolded and misfolded protein in the ER, and the UPR 154 
is activated to resolve ER stress and restore homeostasis. The UPR inhibits protein synthesis, 155 
promotes protein re-folding, and induces degradation of unfolded and misfolded proteins 156 
through ER-associated protein degradation (ERAD) and autophagy (Figure 2). If these survival 157 
mechanisms are unsuccessful, the UPR can induce apoptosis [56]. The major regulators of the 158 
UPR are the ER-membrane resident proteins PERK (protein kinase RNA-like endoplasmic 159 
reticulum kinase), inositol-requiring transmembrane kinase endonuclease 1 (IRE1) and 160 
activated transcription factor (ATF)6. When inactive these proteins are bound to binding 161 
immunoglobulin protein (BiP), also known as glucose regulated protein 78 (GRP78) [57]. 162 
During ER stress, BiP binds to misfolded proteins in the ER and dissociates from the ER-163 
membrane resident proteins to allow their transition to an active state [57] (Figure 2).  164 
When active, PERK phosphorylates elongation initiation factor 2 (EIF2), to inhibit general 165 
protein synthesis [58] and specifically up-regulates ATF4 [59]. ATF4 in turn transcriptionally 166 
up-regulates several other UPR genes including CCAAT/enhancer-binding protein (C/EBP) 167 
homologous protein (CHOP) [60,61] (Figure 2). CHOP is also a transcription factor that 168 
regulates several other UPR genes, and under conditions of prolonged ER stress can promote 169 
apoptosis [60,61].  170 
IRE1 exists in two forms: IRE1 that is ubiquitously expressed and IRE1β that is only expressed 171 
in the GI tract and lung epithelial cells [62]. During ER stress, IRE1 is activated through 172 
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 9 
dimerization and auto-phosphorylation [63,64]. The IRE1 RNase domain is essential for 173 
creating transcriptionally activate XBP1 messenger RNA (mRNA) via splicing, which acts as a 174 
transactivator of UPR genes [65–68] (Figure 2) . IRE1 endoribonuclease activity also facilitates 175 
degradation of specific mRNA in a process known as RIDD (regulated IRE1-dependent decay) 176 
[69].  177 
ATF6 translocates to the Golgi apparatus once released from its complex with BiP [70]. This 178 
allows cleavage by site 1 and site 2 proteases (S1P and S2P), which releases the 179 
transcriptionally active cytoplasmic domain of ATF6 (ATF6-N) that induces UPR-associated 180 
genes [71–73] (Figure 2). Among the ATF6 upregulated genes are CHOP and XBP1 [74].  181 
ER-stress, UPR and intestinal inflammation  182 
Genetic studies have identified several ER-stress/UPR genes associated with IBD [75]. 183 
Moreover, ER-stress levels are increased in ileal and colonic biopsies from CD patients, with 184 
higher than normal levels of BiP, chaperone protein Gp96, and spliced XBP1 observed [9,76–185 
78] (Table 1). Several studies have focused on IRE1-XBP1 signalling in murine models. In mice 186 
with targeted deletion of XBP1 in intestinal epithelial cells (IECs) (XBP1ΔIEC mice), spontaneous 187 
inflammation of the small intestine, increased susceptibility to DSS-induced colitis and 188 
elevated levels of ER stress were observed [9] (Table 1). Furthermore, in XBP1ΔIEC mice 189 
increased levels of apoptosis were observed along with reduced goblet cell and Paneth cell 190 
numbers, leading to decreased production of host defence peptides and higher susceptibility 191 
to Listeria monocytogenes infection [9] (Table 1).  XBP1 has also been shown to suppress 192 
experimental colitis-associated cancer [79], and is essential for efficient TLR-mediated pro-193 
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inflammatory responses to infection in macrophages [80]. These studies support XBP1 as a 194 
key component of the protective function of IECs and macrophages.  195 
Although the UPR acts to maintain ER-homeostasis, hyper-activation of certain UPR 196 
components can create a pro-inflammatory state. In XBP1ΔIEC mice increased activation of 197 
IRE1, causes hyper activation of NFκB, and spontaneous inflammation [45] (Table 1). IRE1β 198 
knock-out mice have enhanced sensitivity to DSS-induced colitis [81] and exhibit goblet cell 199 
abnormalities with exaggerated MUC2 accumulation (Table 1). In contrast, IRE1 knock-out 200 
mice have normal goblet cells [82]. In murine Paneth cells, IRE1 and IRE1β have distinct roles 201 
with hyper activation of IRE1 driving CD-like ileitis, and IRE1β having a protective role [24]. 202 
Association of aberrant PERK-EIF2 and ATF6 pathways with intestinal inflammation have 203 
also been identified. A mouse model expressing non-phosphorylatable EIF2 in IECs resulted 204 
in functional abnormalities in Paneth cells and increased susceptibility to Salmonella infection 205 
and DSS-induced colitis [83] (Table 1). ATF6 deficient mice exhibit increased ER stress as 206 
indicated by elevated levels of BiP, ATF4, CHOP and spliced XBP1, which result in enhanced 207 
sensitivity to DSS-induced colitis [84] (Table 1). Additionally, hypomorphoic mutation in 208 
membrane-bound transcription factor peptidase S1P-encoding gene (Mbtps1), which encodes 209 
the S1P responsible for cleavage of ATF6, causes enhanced susceptibility to DSS-induced 210 
colitis [85]. Although there is less evidence to support a role for PERK-EIF2 and ATF6 211 
pathways in IBD pathogenesis, their importance for ER stress responses in the intestinal 212 
epithelium is clear.  213 
ER-stress and intestinal barrier function 214 
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In the intestinal epithelium, cells that naturally secrete large amounts of protein, such as 215 
Paneth cells and goblet cells, are more susceptible to ER-stress and therefore rely heavily on 216 
the UPR to maintain homeostasis. MUC2 is the major component of mucin that is produced 217 
in goblet cells and secreted into the intestinal lumen. Winnie mice are characterised by a 218 
missense mutation in MUC2, which causes abnormalities in goblet cells, leading to aberrant 219 
mucous production and spontaneous colitis, and association with MUC2 variants has been 220 
identified in IBD patients [86]. Winnie mice also exhibit severe ER stress in goblet cells [10], 221 
which causes up to four-fold increase in activated dendritic cells in the colonic lamina propria, 222 
and aberrant adaptive immune responses associated with  interleukin (IL)-23/Th17  [87]. 223 
Goblet cell abnormalities are also apparent in mice deficient in UPR transcription factor 224 
OASIS, which causes increased ER stress and susceptibility to DSS-induced colitis [88,89]. 225 
AGR2 is an ER resident protein highly expressed in goblet and Paneth cells and regulates the 226 
formation of disulphide bonds in mature proteins. AGR2-/- mice exhibit a decreased number 227 
of goblet cells and MUC2 production, Paneth cell abnormalities, elevated ER-stress and 228 
spontaneous colitis [90]. Notably, AGR2 is decreased in patients with CD and UC [11]. These 229 
studies highlight the key role of intestinal secretory cells and breakdown of intestinal barrier 230 
function in IBD pathogenesis.  231 
Functional intersection between autophagy and the UPR 232 
The UPR and autophagy are intimately linked processes. In a range of Intestinal epithelial cells, 233 
chemical ER-stress inducers activate autophagy, modulated by enhanced expression of CHOP 234 
and stimulation of the IRE1 pathway [91]. In endothelial cells, IRE1-dependent splicing of 235 
XBP1 mRNA activated autophagy via up-regulation of Beclin-1, which is a major regulator of 236 
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the autophagy pathway [92] (Figure 3). Contrary to expectation, XBP1 deletion in a familial 237 
amyotrophic lateral sclerosis mouse model increased autophagy, which enhanced clearance 238 
of accumulated toxic superoxide dismutase-1 (SOD1) aggregates [93]. It was suggested that 239 
in this scenario, autophagy is induced in a compensatory manner due to attenuated UPR. 240 
The UPR and autophagy also intersect at the PERK-EIF2-ATF4 pathway [94–99]. In an in vitro 241 
model of osteosarcoma, PERK induced autophagy via mechanistic target of rapamycin 242 
(mTORC1) inhibition to promote survival in response to ER stress-conferred chemoresistance 243 
to apoptosis [95] (Figure 3). Additionally, PERK modulates autophagy via AMPK-dependent 244 
inhibition of mTORC1 in response to extracellular matrix (ECM) detachment in mammary 245 
epithelial cells (MECs) [94]. One of the main functional outcomes of PERK signalling is reduced 246 
protein synthesis. Inhibition of mTORC1 helps to promote this effect as mTORC1 controls 247 
synthesis of ~15-20% of protein within the cell [100].  Thus, via modulation of mTORC1, PERK 248 
signalling achieves dual outcomes; inhibition of protein synthesis and induction of autophagy 249 
to degrade misfolded proteins. 250 
During amino acid deprivation, ATF4 and CHOP can bind specific C/EBP-ATF Response 251 
Elements (CAREs), also known as Amino Acid Response Elements (AAREs) and CHOP-Response 252 
Elements (CHOP-REs) to induce transcription of a wide range of autophagy genes [101] (Figure 253 
3). In other studies, hypoxia or ECM detachment induced PERK-dependent autophagy due to 254 
autophagy gene up-regulation via ATF4 and CHOP [102–104]. This up-regulation of autophagy 255 
gene transcription by the UPR was shown to replenish autophagy proteins to promote survival 256 
during cellular stress [103].  257 
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ATF6 has also been implicated mechanistically in autophagy regulation. In response to cellular 258 
stress, interferon (IFN)-γ activates the Ask1 (Apoptosis signal-regulating kinase 1)/MAPK 259 
(Mitogen-activated protein kinase) pathway, which phosphorylates ATF6 to allow its 260 
proteolytic activation [105]. ATF6 interaction with C/EBP-β is essential for IFN-γ-induced up-261 
regulation of DAPK1 (death-associated protein kinase 1), which can subsequently stimulate 262 
autophagy [106] (Figure 3). Mice lacking either ATF6 or Ask1 are highly susceptible to bacterial 263 
infection due to defective autophagy [105,106]. Furthermore, ATF6 recruitment of DAPK1 in 264 
response to ER stress enhanced xenophagy in human colonic biopsies and epithelial cells, 265 
which was attenuated in cells harbouring the ATG16L1 T300A SNP [107]. Additionally, 266 
activated ATF6 was shown to stimulate Akt (protein kinase B), which resulted in the inhibition 267 
of mTORC1 [108,109] (Figure 3). 268 
In a recent study in MCF-7 human breast cancer cells, ER stress induced by the chemo-269 
preventative agent ursolic acid (UA) was associated with autophagy activation [99]. UA 270 
induced autophagy via MAPK1/3 signalling and subsequent promotion of PERK signalling, 271 
resulting in the inhibition of apoptosis. Furthermore, a study in human ovarian cancer cells 272 
showed interdependent activation of autophagy and the PERK-EIF2 UPR pathway when 273 
treated with metformin, which causes energy starvation [98]. In these scenarios an 274 
unconventional relationship between autophagy and ER stress was uncovered, which remains 275 
to be mechanistically solved. Nonetheless, under these circumstances the interaction of the 276 
UPR and autophagy pathways has pro-survival outcomes.  277 
Convergence of autophagy, ER-stress and CD  278 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 14 
In an attempt to relieve ER-stress the UPR can induce autophagy to degrade misfolded 279 
proteins, protein aggregates and damaged organelles [91,110–113]. Autophagy activity is 280 
increased in highly secretory Paneth cells [45] to counterbalance high levels of  ER-stress 281 
[112], thus ER-stress is a significant risk in these cells when the UPR or autophagy is not 282 
functional. Consistent with this, in Paneth cells of CD patients harbouring ATG16L1 T300A risk 283 
alleles, BiP and pEIF2α are highly expressed [46] (Table 1). Significantly, ATG16L1;XBP1ΔIEC 284 
mice develop similar phenotypic ileitis to ATG16L1ΔIEC mice, but earlier in life due to increased 285 
ER stress [24,45].  286 
ERAD can regulate the degradation of IRE1 to prevent accumulation of toxic IRE1 287 
aggregates, however persistent ER-stress will inhibit ERAD degradation of IRE1 [24]. When 288 
this occurs, autophagy plays an important role in the clearance of supramolecular clusters of 289 
IRE1 (Figure 3). In ATG16L1ΔIEC mice, development of spontaneous CD-like ileitis is associated 290 
with defective autophagy resulting in toxic accumulation of IRE1 in Paneth cells [24] (Table 291 
1). Furthermore, the selective autophagy receptor optineurin interacts with IRE1α, and 292 
optineurin deficiency amplified the accumulation of IRE1α [24]. In humans homozygous for 293 
ATG16L1 T300A, a similar accumulation of IRE1 was observed in intestinal epithelial crypts 294 
[24] (Table 1). This has led to suggestion that the ATG16L1 T300A SNP may define a specific 295 
subtype of patients with CD, characterised by Paneth cell ER-stress [46].  This synergistic and 296 
compensatory relationship between the UPR and autophagy is affirmed by the presence of 297 
CD-associated SNPs in ATG16L1 and XBP1.  298 
A recent study has demonstrated a direct link between NOD1/2 and the IRE1 pathway in the 299 
context of ER-stress-induced inflammation [114]. When active, IRE1 stimulates the c-Jun N-300 
terminal kinase (JNK) pathway and recruits TRAF2 (TNF receptor-associated factor 2) to the 301 
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ER membrane to trigger NFκB signalling [115,116] and autophagy induction [112,117,118] 302 
(Figure 3). In mouse and human cells, ER-stress induced by chemicals or infection with 303 
Brucella abortus and Chlamydia muridarum increased inflammation and IL-6 production 304 
[114]. This response was dependent on NOD1/2 and receptor-interacting serine/threonine-305 
protein kinase 2 (RIPK2), but also on IRE1 kinase activity and TRAF2-induced NFκB signalling 306 
[114]. This suggests there is a functional intersection between the IRE1 pathway and 307 
NOD1/2 signalling, which is facilitated by TRAF2 (Figure 3).  308 
Interestingly, an additional study has shown that ER-stress responses can be modulated by 309 
another innate immune sensor called stimulator of interferon genes (STING) in response to 310 
cyclic-di-AMP (c-di-AMP), a vita-PAMP (pathogen associated molecular pattern) present in 311 
live Gram-positive bacteria [119]. This process induces autophagy via inhibition of the major 312 
autophagy suppressor mTORC1 and localisation of STING to autophagosomes. 313 
Pharmacological induction of autophagy and the UPR 314 
A recent review estimated IBD treatment costs of £720 million ($940m) per year in the United 315 
Kingdom alone [120], with roughly a quarter of these costs directly attributed to drug 316 
treatments [121]. The efficacy of these drugs continues to come under scrutiny as response 317 
to treatment often diminishes over time, with a review of worldwide cohorts estimating that 318 
between 10–35% of CD patients required surgery within a year of diagnosis and up to 61% by 319 
10 years [122]. In order to improve the efficacy of IBD treatment, optimization of existing 320 
clinical therapies and the development of novel therapeutics is required. 321 
The convergence between autophagy and UPR pathways provides new opportunity for the 322 
treatment of IBD and the modulation of the UPR in combination with autophagy inducers is a 323 
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promising therapeutic strategy. There is evidence that inducing autophagy can have 324 
therapeutic benefits for the treatment of IBD [26] with several studies investigating the utility 325 
of autophagy inducers as adjuvant therapies. Rapamycin analogues, sirolimus and everolimus, 326 
inhibit mTORC1 to induce autophagy and are already approved for clinical use for post-327 
transplantation (e.g. liver and renal) management. In IL-10-deficient mice, everolimus 328 
treatment alleviated spontaneous colitis and reduced CD4+ T cells and IFN-γ [123]. In a case 329 
study sirolimus improved symptoms and intestinal healing in a patient with severe refractory 330 
CD [124]. In another case study, symptoms were controlled for 18 months with everolimus 331 
treatment in a refractory UC patient [125]. Moreover, in a study of refractory paediatric IBD, 332 
sirolimus induced clinical remission in 45% of UC patients and 100% of CD patients; albeit the 333 
sample size was small [126]. Significantly, everolimus had comparable safety and tolerability 334 
as azathioprine when used to maintain steroid-induced remission in a cohort of adult CD 335 
patients [127]. As these mTORC1 inhibitors are already approved for clinical use, they have 336 
been investigated the most extensively, however there are a plethora of novel autophagy 337 
modulators that are currently being developed, characterised and patented for therapeutic 338 
use in a range of diseases including IBD [128,129].  339 
Recent progress has also been made to identify specific chemical inducers of the UPR. A 340 
screen of 1,200 FDA-approved compounds carried out in C.elegans identified eight 341 
compounds that induced UPR responses, four of which specifically increased mitochondrial 342 
UPR [130]. The identified drugs included antirheumatic agents, antianginal calcium channel 343 
blockers; androgen receptor inhibitors used for cancer therapy and tetracycline antibiotics. 344 
A well-characterised modulator of the UPR, tauroursodeoxycholic acid (TUDCA), that 345 
promotes protein refolding to reduce ER-stress, was shown to ameliorate DSS-induced colitis 346 
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in mice by decreasing ER-stress in IECs [84]. Furthermore, a selective inhibitor of eIF2α 347 
dephosphorylation protects cells from ER-stress and ameliorates murine experimental colitis 348 
[131,132]. Supplementation with glutamine has also been suggested for the improvement of 349 
IBD treatment, as this amino acid was shown to dampen experimental colitis in rats by 350 
inhibiting ER-stress in colonic epithelial cells [133].   351 
Drugs used to treat metabolic disorders have also been investigated for UPR inducing 352 
properties. The biguanides metformin and phenformin have been implicated in induction of 353 
the UPR and resolution of ER-stress via activation of AMPK, which subsequently stimulated  354 
IRE1α and PERK pathways [98,134,135]. Inhibitors of dipeptidyl peptidase IV (DPP4), including 355 
gemigliptin, also prevented ER-stress-mediated apoptosis by promoting IRE1α and PERK 356 
pathways [136]. Furthermore, agonists of the glucagon-like peptide-1 receptor, such as 357 
exenatide, relieved ER stress via up-regulation of ATF4 expression [137]. Exogenous chemical 358 
chaperones have also been explored as a method to relieve ER stress by mimicking ER 359 
chaperones to promote protein transport and re-folding capacity [138]. 360 
Although several studies have demonstrated beneficial effects of enhancing UPR function for 361 
intestinal homeostasis, future investigations should proceed with caution. For example, 362 
hyper-activation of the UPR kinase IRE1α can exacerbate intestinal inflammation, as seen in 363 
patients with ATG16L1 and NOD2 mutations, therefore, in certain circumstances 364 
pharmacological inhibition of UPR receptors would be a more effective strategy [24,45,114] 365 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
Of particular interest, the selective autophagy cargo receptor optineurin forms a critical link 366 
between ER-stress resolution and autophagy due to its role in the degradation of IRE1α 367 
aggregates [24], and another recently identified autophagy cargo receptor that is integral for 368 
resolution of ER-stress, CCPG1, mediates ER-phagy to remove damaged ER membranes [23]. 369 
Understanding the biology and functions of adaptors such as optineurin and CCPG1 may 370 
identify novel druggable targets and expedite development of the next generation of 371 
therapeutics aimed at modulation of the UPR in combination with autophagy.  372 
Discussion 373 
The complexity of IBD is evident from the large number of risk loci identified by genetic 374 
studies, and the diverse health profile of patients that are affected. Mouse models of IBD 375 
cannot emulate the human disease, however they are useful tools to explore how specific 376 
gene mutations influence inflammation. Interestingly, as highlighted in (Table 1) the majority 377 
of mouse models mimicking IBD-associated genetic risk do not develop spontaneous 378 
inflammation, but rather they are sensitised to DSS-induced colitis, which acts by damaging 379 
the epithelium and increasing intestinal permeability.  The intestinal epithelium has 380 
important immunoregulatory functions and controls the equilibrium between tolerance and 381 
immunity to non-self-antigens [139]. As such breakdown of intestinal epithelial barrier 382 
function and concomitant interaction with environmental factors in the lumen is a trigger for 383 
inflammation. The intestinal lumen comprises a multitude of potential triggers including the 384 
microbiota, dietary antigens, and luminal antigens. Additional triggers may be host-derived 385 
factors that are released into the lumen as the intestinal epithelial barrier breaks down.  These 386 
so-called Damage-Associated Molecular Patterns (DAMPS) include intracellular proteins, such 387 
as high-mobility group box 1 (HMGB1), heat-shock proteins and components derived from 388 
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the extracellular matrix. Examples of non-protein DAMPs include genomic DNA, 389 
mitochondrial DNA, RNA, uric acid and ATP [140,141]. Not surprisingly, there is considerable 390 
interest in developing novel therapeutic strategies aimed at re-establishing intestinal barrier 391 
function [142] and modulation of DAMPs for the treatment of IBD [140]. 392 
Dysbiosis of the gut microbiome is strongly implicated in the pathogenesis of CD [143], and it 393 
has been suggested that microbial dysbiosis may be an environmental trigger.  A recent study 394 
by Tschurtschenthaler and colleagues [24] addressed this question. Although microbial 395 
dysbiosis was present in the ileum of Atg16l1;Xbp1ΔIEC mice, such structural alteration of the 396 
microbiota did not trigger ileitis but, rather, aggravated DSS-induced colitis [24].  In order to 397 
understand the role of the environment in disease, determining the relative contribution of 398 
genetics and a detailed characterization of environmental triggers is required.  399 
Greater understanding of the genetic factors that underlie CD pathogenesis are leading to 400 
improvements in treatment. Development of personalised therapies may be achieved via 401 
genotyping for key SNPs in genes involved in both the autophagy and UPR pathways. IBD 402 
drugs already established in the clinic have been shown to exert their effects, at least in-part, 403 
through the modulation of autophagy [26] or the UPR, and establishing patient genotypes 404 
may help predict response. For example, recent studies have identified an association 405 
between ATG16L1 T300A SNP and an enhanced therapeutic effect of thiopurines [144] and 406 
anti-TNF-α therapy [145]. Interestingly, the immunoregulatory effects of these drugs were 407 
associated with autophagy stimulation [144,146,147] and the T300A genotype has been 408 
associated with a subset of patients that exhibit deficiencies in both the UPR and autophagy 409 
[46]. Furthermore, CD patients harbouring NOD2 mutations associate with better clinical 410 
outcomes  in response to thiopurines, whereas CD patients with wild-type NOD2 respond 411 
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better to steroids and anti-TNF therapy [148]. Due to the genetic complexity of IBD and 412 
epistasis between genes, it is imperative that multiple genes are analysed for the purpose of 413 
patient stratification. For example, a recent study identified a 32-gene transcriptomic 414 
signature in lymphoblastoid cells that was able to predict lack of response to thiopurines, with 415 
aberrant cell cycle control, DNA mismatched repair and RAC1-dependent mechanisms 416 
implicated in thiopurine resistance [149]. Furthermore, it is increasingly clear that  epigenetic, 417 
microRNA and immune cell signatures among others will have a significant role to play in 418 
predicting disease susceptibility and response to therapy [150–152].  419 
With regards to the intestinal microbiota, a recent study has characterised microbial 420 
signatures for the diagnosis of IBD that were highly sensitive and could differentiate CD 421 
patients from healthy controls and UC patients. This study highlights the potential for using 422 
the intestinal microbiota as a micro-biomarker [153]. Importantly, as many drugs need to be 423 
metabolised and de-toxified by the gut microbiota, this approach could also have application 424 
in predicting response to therapy. Given that dysregulation of autophagy and ER-stress can 425 
affect the intestinal microbial environment, analysis of microbial signatures may help to 426 
determine if a patient would benefit from drugs that modulate the autophagy or UPR 427 
pathways.  428 
To conclude, the ER-stress/UPR and autophagy pathways play a vital role in the maintenance 429 
of intestinal homeostasis and breakdown of these converging pathways has been implicated 430 
in persistent intestinal infections, chronic inflammation and dysregulated immune responses 431 
observed in IBD. Therefore, strategies aimed at modulating these pathways simultaneously 432 
may prove to be an effective therapeutic option.  433 
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Figure Legends  438 
Figure 1: Autophagy pathway and autophagosome biogenesis 439 
During the initial stages of autophagy, the isolation membrane forms a double membrane 440 
vesicle (the autophagosome) around the cargo to be degraded. ULK complex (ULK1-ULK2-441 
ATG13-FIP200-ATG101) and Beclin 1 (Vps34-Vps150-Beclin1) complex, through interaction 442 
with ATG14, recruit autophagy proteins and complexes to the autophagosome membrane. 443 
ATG12 is conjugated to ATG5 and forms a complex with ATG16L1 (ATG16L1 complex). The 444 
ATG16L1 complex is proposed to specify the site of LC3 lipidation for autophagosome 445 
formation. LC3 is conjugated to PE to form lipidated LC3-II and is associated with the 446 
autophagosome outer membrane. Upon autophagosome closure, LC3 localises to the inner 447 
membrane and other autophagy proteins and complexes dissociate for recycling. The mature 448 
autophagosome then fuses with a lysosome to form an autophagolysosome, in which cargo 449 
are degraded by lysosomal enzymes and subunits are recycled.  450 
Figure 2: The unfolded protein response 451 
BiP chaperone protein binds unfolded/misfolded proteins in the ER and dissociates from 452 
transmembrane receptors upon accumulation of the toxic proteins. The transmembrane 453 
receptors PERK, IRE1α and ATF6 become activated. PERK phosphorylates EIF2α, which 454 
downregulates global translation but specifically upregulates ATF4 and CHOP that upregulate 455 
UPR-associated genes. IRE1α splices XBP1 to its active form and ATF6 is cleaved by S1P and 456 
S2P to active ATF6-N, which both translocate to the nucleus to upregulate UPR-associated 457 
genes. The main function of these UPR-associated genes is to increase protein refolding, 458 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 23 
inhibit synthesis of new protein and degrade unfolded/misfolded proteins through autophagy 459 
and ERAD.  460 
Figure 3: Intersection between autophagy and the unfolded protein response 461 
ER stress activates transmembrane receptors PERK, IRE1α and ATF6. PERK phosphorylates 462 
EIF2α, which specifically upregulates ATF4 and CHOP that bind AAREs and CHOP-Res to 463 
upregulate autophagy genes. PERK also induces autophagy via mTORC1 inhibition. IRE1α 464 
splices XBP1 to its active form, which up-regulates Beclin-1.  IRE1α endonuclease activity 465 
activates the JNK pathway, which induces autophagy via TRAF2, NOD2 and NFκB. Enhanced 466 
autophagy degrades accumulated IRE1α clusters. Active ATF6-N induces autophagy via 467 
mTORC1 inhibition and binds C/EBP-β to up-regulate DAPK1.  468 
Table 1: Murine models of intestinal inflammation  469 
Links between autophagy, ER-stress/UPR and experimental colitis/intestinal inflammation 470 
and IBD. 471 
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Figure 2  476 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 26 
 477 
Figure 3  478 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 27 
479 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 28 
Table 1  480 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 29 
References 481 
1  Gasparetto M, Guariso G. Highlights in IBD Epidemiology and Its Natural History in the 482 
Paediatric Age. Gastroenterol Res Pr 2013;2013:829040. doi:10.1155/2013/829040 483 
2  Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects 484 
and treatments. J Inflamm Res 2014;7:113–20. doi:10.2147/JIR.S65979 485 
3  Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol 486 
Hepatol 2017;14:nrgastro.2016.208. doi:10.1038/nrgastro.2016.208 487 
4  Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn’s disease. F1000Prime Rep 488 
2015;7:44. doi:10.12703/p7-44 489 
5  Zuo T, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory 490 
Bowel Disease. Front Microbiol 2018;9:2247. doi:10.3389/fmicb.2018.02247 491 
6  Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive 492 
Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 493 
2004;127:412–21. doi:10.1053/j.gastro.2004.04.061 494 
7  Lange KM de, Moutsianas L, Lee JC, et al. Genome-wide association study implicates 495 
immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 496 
2017;49:256–61. doi:10.1038/ng.3760 497 
8  Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the 498 
number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010;42:1118–25. 499 
doi:10.1038/ng.717 500 
9  Kaser A, Lee A-H, Franke A, et al. XBP1 Links ER Stress to Intestinal Inflammation and 501 
Confers Genetic Risk for Human Inflammatory Bowel Disease. Cell 2008;134:743–56. 502 
doi:10.1016/j.cell.2008.07.021 503 
10  Heazlewood CK, Cook MC, Eri R, et al. Aberrant Mucin Assembly in Mice Causes 504 
Endoplasmic Reticulum Stress and Spontaneous Inflammation Resembling Ulcerative 505 
Colitis. PLoS Med 2008;5. doi:10.1371/journal.pmed.0050054 506 
11  Zheng W, Rosenstiel P, Huse K, et al. Evaluation of AGR2 and AGR3 as candidate genes for 507 
inflammatory bowel disease. Genes Immun 2006;7:11–8. doi:10.1038/sj.gene.6364263 508 
12  Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev 509 
Mol Cell Biol 2018;19:349. doi:10.1038/s41580-018-0003-4 510 
13  Lamb CA, Yoshimori T, Tooze SA. The autophagosome: origins unknown, biogenesis 511 
complex. Nat Rev Mol Cell Biol 2013;14:759–74. doi:10.1038/nrm3696 512 
14  Zaffagnini G, Martens S. Mechanisms of Selective Autophagy. J Mol Biol 2016;428:1714–513 
24. doi:10.1016/j.jmb.2016.02.004 514 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 30 
15  Nys K, Agostinis P, Vermeire S. Autophagy: a new target or an old strategy for the 515 
treatment of Crohn’s disease? Nat Rev Gastroenterol Hepatol 2013;10:395–401. 516 
doi:10.1038/nrgastro.2013.66 517 
16  Dupont N, Lacas-Gervais S, Bertout J, et al. Shigella phagocytic vacuolar membrane 518 
remnants participate in the cellular response to pathogen invasion and are regulated by 519 
autophagy. Cell Host Microbe 2009;6:137–49. doi:10.1016/j.chom.2009.07.005 520 
17  Thurston TLM, Ryzhakov G, Bloor S, et al. The TBK1 adaptor and autophagy receptor 521 
NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat Immunol 522 
2009;10:1215–21. doi:10.1038/ni.1800 523 
18  Wild P, Farhan H, McEwan DG, et al. Phosphorylation of the autophagy receptor 524 
optineurin restricts Salmonella growth. Science 2011;333:228–33. 525 
doi:10.1126/science.1205405 526 
19  Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. 527 
Autophagy 2011;7:279–96. 528 
20  Filimonenko M, Isakson P, Finley KD, et al. The selective macroautophagic degradation of 529 
aggregated proteins requires the PI3P-binding protein Alfy. Mol Cell 2010;38:265–79. 530 
doi:10.1016/j.molcel.2010.04.007 531 
21  Kirkin V, Lamark T, Sou Y-S, et al. A role for NBR1 in autophagosomal degradation of 532 
ubiquitinated substrates. Mol Cell 2009;33:505–16. doi:10.1016/j.molcel.2009.01.020 533 
22  Newman AC, Scholefield CL, Kemp AJ, et al. TBK1 kinase addiction in lung cancer cells is 534 
mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-κB signalling. PloS One 535 
2012;7:e50672. doi:10.1371/journal.pone.0050672 536 
23  Smith MD, Harley ME, Kemp AJ, et al. CCPG1 Is a Non-canonical Autophagy Cargo 537 
Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis. Dev Cell 2018;44:217-538 
232.e11. doi:10.1016/j.devcel.2017.11.024 539 
24  Tschurtschenthaler M, Adolph TE, Ashcroft JW, et al. Defective ATG16L1-mediated 540 
removal of IRE1α drives Crohn’s disease–like ileitis. J Exp Med 2017;214:401–22. 541 
doi:10.1084/jem.20160791 542 
25  Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27–42. 543 
doi:10.1016/j.cell.2007.12.018 544 
26  Hooper KM, Barlow PG, Stevens C, et al. Inflammatory Bowel Disease Drugs: A Focus on 545 
Autophagy. J Crohns Colitis 2017;11:118–27. doi:10.1093/ecco-jcc/jjw127 546 
27  Ke P, Shao B-Z, Xu Z-Q, et al. Intestinal Autophagy and Its Pharmacological Control in 547 
Inflammatory Bowel Disease. Front Immunol 2017;7. doi:10.3389/fimmu.2016.00695 548 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 31 
28  Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of 549 
nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat 550 
Genet 2007;39:207–11. doi:10.1038/ng1954 551 
29  Cadwell K, Patel KK, Maloney NS, et al. Virus-Plus-Susceptibility Gene Interaction 552 
Determines Crohn’s Disease Gene Atg16L1 Phenotypes in Intestine. Cell 2010;141:1135–553 
45. doi:10.1016/j.cell.2010.05.009 554 
30  Cadwell K, Liu J, Brown SL, et al. A unique role for autophagy and Atg16L1 in Paneth cells 555 
in murine and human intestine. Nature 2008;456:259–63. doi:10.1038/nature07416 556 
31  Lassen KG, Kuballa P, Conway KL, et al. Atg16L1 T300A variant decreases selective 557 
autophagy resulting in altered cytokine signaling and decreased antibacterial defense. 558 
Proc Natl Acad Sci U A 2014;111:7741–6. doi:10.1073/pnas.1407001111 559 
32  Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen 560 
induced by a Crohn’s disease associated ATG16L1 variant. PLoS One 2008;3:e3391. 561 
doi:10.1371/journal.pone.0003391 562 
33  Singh SB, Davis AS, Taylor GA, et al. Human IRGM induces autophagy to eliminate 563 
intracellular mycobacteria. Science 2006;313:1438–41. doi:10.1126/science.1129577 564 
34  Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in IRGM alters a binding site 565 
for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. 566 
Nat Genet 2011;43:242–5. doi:10.1038/ng.762 567 
35  Gardet A, Benita Y, Li C, et al. LRRK2 is involved in the IFN-gamma response and host 568 
response to pathogens. J Immunol 2010;185:5577–85. doi:10.4049/jimmunol.1000548 569 
36  Marcuzzi A, Bianco AM, Girardelli M, et al. Genetic and functional profiling of Crohn’s 570 
disease: autophagy mechanism and susceptibility to infectious diseases. Biomed Res Int 571 
2013;2013:297501. doi:10.1155/2013/297501 572 
37  Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants 573 
with susceptibility to Crohn’s disease. Nature 2001;411:599–603. doi:10.1038/35079107 574 
38  Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new 575 
susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. 576 
Nat Genet 2007;39:596–604. doi:10.1038/ng2032 577 
39  Weersma RK, Stokkers PCF, van Bodegraven AA, et al. Molecular prediction of disease risk 578 
and severity in a large Dutch Crohn’s disease cohort. Gut 2009;58:388–95. 579 
doi:10.1136/gut.2007.144865 580 
40  Travassos LH, Carneiro LAM, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by 581 
recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 582 
2010;11:55–62. doi:10.1038/ni.1823 583 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 32 
41  Chauhan S, Mandell MA, Deretic V. IRGM governs the core autophagy machinery to 584 
conduct antimicrobial defense. Mol Cell 2015;58:507–21. 585 
doi:10.1016/j.molcel.2015.03.020 586 
42  Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells 587 
influencing bacterial handling and antigen presentation. Nat Med 2010;16:90–7. 588 
doi:10.1038/nm.2069 589 
43  Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-590 
dependent, anti-bacterial pathway implicated in Crohn’s disease pathogenesis. 591 
Gastroenterology 2010;139:1630-1641.e2. doi:10.1053/j.gastro.2010.07.006 592 
44  Wolfkamp SC, Verseyden C, Vogels EW, et al. ATG16L1 and NOD2 polymorphisms 593 
enhance phagocytosis in monocytes of Crohn’s disease patients., ATG16L1 and NOD2 594 
polymorphisms enhance phagocytosis in monocytes of Crohn’s disease patients. World J 595 
Gastroenterol World J Gastroenterol WJG 2014;20, 20:2664, 2664–72. 596 
doi:10.3748/wjg.v20.i10.2664, 10.3748/wjg.v20.i10.2664 597 
45  Adolph TE, Tomczak MF, Niederreiter L, et al. Paneth cells as a site of origin for intestinal 598 
inflammation. Nature Published Online First: 2 October 2013. doi:10.1038/nature12599 599 
46  Deuring JJ, Fuhler GM, Konstantinov SR, et al. Genomic ATG16L1 risk allele-restricted 600 
Paneth cell ER stress in quiescent Crohn’s disease. Gut 2014;63:1081–91. 601 
doi:10.1136/gutjnl-2012-303527 602 
47  Kobayashi KS. Nod2-Dependent Regulation of Innate and Adaptive Immunity in the 603 
Intestinal Tract. Science 2005;307:731–4. doi:10.1126/science.1104911 604 
48  Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal 605 
Crohn’s disease. Proc Natl Acad Sci U S A 2005;102:18129–34. 606 
doi:10.1073/pnas.0505256102 607 
49  Liu B, Gulati AS, Cantillana V, et al. Irgm1-deficient mice exhibit Paneth cell abnormalities 608 
and increased susceptibility to acute intestinal inflammation. Am J Physiol - Gastrointest 609 
Liver Physiol 2013;305:G573–84. doi:10.1152/ajpgi.00071.2013 610 
50  Zhang Q, Pan Y, Yan R, et al. Commensal bacteria direct selective cargo sorting to promote 611 
symbiosis. Nat Immunol 2015;16:918–26. doi:10.1038/ni.3233 612 
51  Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances 613 
endotoxin-induced IL-1β production. Nature 2008;456:264–8. doi:10.1038/nature07383 614 
52  Zhang H, Zheng L, McGovern DPB, et al. Myeloid ATG16L1 Facilitates Host-Bacteria 615 
Interactions in Maintaining Intestinal Homeostasis. J Immunol Baltim Md 1950 616 
2017;198:2133–46. doi:10.4049/jimmunol.1601293 617 
53  Mizoguchi A, Bhan AK. Immunobiology of B Cells in Inflammatory Bowel Disease. In: 618 
Crohn’s Disease and Ulcerative Colitis. Springer, Boston, MA 2012. 161–8. 619 
doi:10.1007/978-1-4614-0998-4_12 620 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 33 
54  Maeda S, Hsu L-C, Liu H, et al. Nod2 mutation in Crohn’s disease potentiates NF-kappaB 621 
activity and IL-1beta processing. Science 2005;307:734–8. doi:10.1126/science.1103685 622 
55  Liu Z, Lee J, Krummey S, et al. The kinase LRRK2 is a regulator of the transcription factor 623 
NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 624 
2011;12:1063–70. doi:10.1038/ni.2113 625 
56  Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta 626 
2013;1833. doi:10.1016/j.bbamcr.2013.06.028 627 
57  Cao SS. Endoplasmic Reticulum Stress and Unfolded Protein Response in Inflammatory 628 
Bowel Disease: Inflamm Bowel Dis 2015;21:636–44. 629 
doi:10.1097/MIB.0000000000000238 630 
58  Guan B-J, Krokowski D, Majumder M, et al. Translational control during endoplasmic 631 
reticulum stress beyond phosphorylation of the translation initiation factor eIF2α. J Biol 632 
Chem 2014;289:12593–611. doi:10.1074/jbc.M113.543215 633 
59  Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA 634 
translation in mammalian cells. Proc Natl Acad Sci U S A 2004;101:11269–74. 635 
doi:10.1073/pnas.0400541101 636 
60  Harding HP, Zhang Y, Bertolotti A, et al. Perk Is Essential for Translational Regulation and 637 
Cell Survival during the Unfolded Protein Response. Mol Cell 2000;5:897–904. 638 
doi:10.1016/S1097-2765(00)80330-5 639 
61  Nishitoh H. CHOP is a multifunctional transcription factor in the ER stress response. J 640 
Biochem (Tokyo) 2012;151:217–9. doi:10.1093/jb/mvr143 641 
62  Wang XZ, Harding HP, Zhang Y, et al. Cloning of mammalian Ire1 reveals diversity in the 642 
ER stress responses. EMBO J 1998;17:5708–17. doi:10.1093/emboj/17.19.5708 643 
63  Shamu CE, Walter P. Oligomerization and phosphorylation of the Ire1p kinase during 644 
intracellular signaling from the endoplasmic reticulum to the nucleus. EMBO J 645 
1996;15:3028–39. 646 
64  Tirasophon W, Lee K, Callaghan B, et al. The endoribonuclease activity of mammalian IRE1 647 
autoregulates its mRNA and is required for the unfolded protein response. Genes Dev 648 
2000;14:2725–36. 649 
65  Calfon M, Zeng H, Urano F, et al. IRE1 couples endoplasmic reticulum load to secretory 650 
capacity by processing the XBP-1 mRNA. Nature 2002;415:92–6. doi:10.1038/415092a 651 
66  Lee A-H, Iwakoshi NN, Glimcher LH. XBP-1 Regulates a Subset of Endoplasmic Reticulum 652 
Resident Chaperone Genes in the Unfolded Protein Response. Mol Cell Biol 653 
2003;23:7448–59. doi:10.1128/MCB.23.21.7448-7459.2003 654 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 34 
67  Lee K, Tirasophon W, Shen X, et al. IRE1-mediated unconventional mRNA splicing and S2P-655 
mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein 656 
response. Genes Dev 2002;16:452–66. doi:10.1101/gad.964702 657 
68  Yoshida H, Matsui T, Yamamoto A, et al. XBP1 mRNA is induced by ATF6 and spliced by 658 
IRE1 in response to ER stress to produce a highly active transcription factor. Cell 659 
2001;107:881–91. 660 
69  Hollien J. Decay of Endoplasmic Reticulum-Localized mRNAs During the Unfolded Protein 661 
Response. Science 2006;313:104–7. doi:10.1126/science.1129631 662 
70  Shen J, Chen X, Hendershot L, et al. ER stress regulation of ATF6 localization by 663 
dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell 664 
2002;3:99–111. 665 
71  Haze K, Yoshida H, Yanagi H, et al. Mammalian transcription factor ATF6 is synthesized as 666 
a transmembrane protein and activated by proteolysis in response to endoplasmic 667 
reticulum stress. Mol Biol Cell 1999;10:3787–99. 668 
72  Li M, Baumeister P, Roy B, et al. ATF6 as a transcription activator of the endoplasmic 669 
reticulum stress element: thapsigargin stress-induced changes and synergistic 670 
interactions with NF-Y and YY1. Mol Cell Biol 2000;20:5096–106. 671 
73  Ye J, Rawson RB, Komuro R, et al. ER stress induces cleavage of membrane-bound ATF6 672 
by the same proteases that process SREBPs. Mol Cell 2000;6:1355–64. 673 
74  Hirsch I, Weiwad M, Prell E, et al. ERp29 deficiency affects sensitivity to apoptosis via 674 
impairment of the ATF6-CHOP pathway of stress response. Apoptosis Int J Program Cell 675 
Death 2014;19:801–15. doi:10.1007/s10495-013-0961-0 676 
75  McGuckin MA, Eri RD, Das I, et al. ER stress and the unfolded protein response in intestinal 677 
inflammation. Am J Physiol - Gastrointest Liver Physiol 2010;298:G820–32. 678 
doi:10.1152/ajpgi.00063.2010 679 
76  Deuring JJ, de Haar C, Koelewijn CL, et al. Absence of ABCG2-mediated mucosal 680 
detoxification in patients with active inflammatory bowel disease is due to impeded 681 
protein folding. Biochem J 2012;441:87–93. doi:10.1042/BJ20111281 682 
77  Rolhion N, Barnich N, Bringer M-A, et al. Abnormally expressed ER stress response 683 
chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion. Gut 684 
2010;59:1355–62. doi:10.1136/gut.2010.207456 685 
78  Shkoda A, Ruiz PA, Daniel H, et al. Interleukin-10 Blocked Endoplasmic Reticulum Stress 686 
in Intestinal Epithelial Cells: Impact on Chronic Inflammation. Gastroenterology 687 
2007;132:190–207. doi:10.1053/j.gastro.2006.10.030 688 
79  Niederreiter L, Fritz TMJ, Adolph TE, et al. ER stress transcription factor Xbp1 suppresses 689 
intestinal tumorigenesis and directs intestinal stem cells. J Exp Med 2013;210:2041–56. 690 
doi:10.1084/jem.20122341 691 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 35 
80  Martinon F, Chen X, Lee A-H, et al. TLR activation of the transcription factor XBP1 692 
regulates innate immune responses in macrophages. Nat Immunol 2010;11:411–8. 693 
doi:10.1038/ni.1857 694 
81  Bertolotti A, Wang X, Novoa I, et al. Increased sensitivity to dextran sodium sulfate colitis 695 
in IRE1β-deficient mice. J Clin Invest 2001;107:585–93. 696 
82  Tsuru A, Fujimoto N, Takahashi S, et al. Negative feedback by IRE1β optimizes mucin 697 
production in goblet cells. Proc Natl Acad Sci U S A 2013;110:2864–9. 698 
doi:10.1073/pnas.1212484110 699 
83  Cao SS, Wang M, Harrington JC, et al. Phosphorylation of eIF2α Is Dispensable for 700 
Differentiation but Required at a Posttranscriptional Level for Paneth Cell Function and 701 
Intestinal Homeostasis in Mice: Inflamm Bowel Dis 2014;20:712–22. 702 
doi:10.1097/MIB.0000000000000010 703 
84  Cao SS, Zimmermann EM, Chuang B, et al. The Unfolded Protein Response and Chemical 704 
Chaperones Reduce Protein Misfolding and Colitis in Mice. Gastroenterology 705 
2013;144:989-1000.e6. doi:10.1053/j.gastro.2013.01.023 706 
85  Brandl K, Rutschmann S, Li X, et al. Enhanced sensitivity to DSS colitis caused by a 707 
hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. 708 
Proc Natl Acad Sci U S A 2009;106:3300–5. doi:10.1073/pnas.0813036106 709 
86  Moehle C, Ackermann N, Langmann T, et al. Aberrant intestinal expression and allelic 710 
variants of mucin genes associated with inflammatory bowel disease. J Mol Med Berl Ger 711 
2006;84:1055–66. doi:10.1007/s00109-006-0100-2 712 
87  Eri RD, Adams RJ, Tran TV, et al. An intestinal epithelial defect conferring ER stress results 713 
in inflammation involving both innate and adaptive immunity. Mucosal Immunol 714 
2011;4:354–64. doi:10.1038/mi.2010.74 715 
88  Asada R, Saito A, Kawasaki N, et al. The Endoplasmic Reticulum Stress Transducer OASIS 716 
Is involved in the Terminal Differentiation of Goblet Cells in the Large Intestine. J Biol 717 
Chem 2012;287:8144–53. doi:10.1074/jbc.M111.332593 718 
89  Hino K, Saito A, Asada R, et al. Increased Susceptibility to Dextran Sulfate Sodium-Induced 719 
Colitis in the Endoplasmic Reticulum Stress Transducer OASIS Deficient Mice. PLoS ONE 720 
2014;9. doi:10.1371/journal.pone.0088048 721 
90  Zhao F, Edwards R, Dizon D, et al. Disruption of Paneth and goblet cell homeostasis and 722 
increased endoplasmic reticulum stress in Agr2−/− mice. Dev Biol 2010;338:270–9. 723 
doi:10.1016/j.ydbio.2009.12.008 724 
91  Shimodaira Y, Takahashi S, Kinouchi Y, et al. Modulation of endoplasmic reticulum (ER) 725 
stress-induced autophagy by C/EBP homologous protein (CHOP) and inositol-requiring 726 
enzyme 1α (IRE1α) in human colon cancer cells. Biochem Biophys Res Commun 727 
2014;445:524–33. doi:10.1016/j.bbrc.2014.02.054 728 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 36 
92  Margariti A, Li H, Chen T, et al. XBP1 mRNA Splicing Triggers an Autophagic Response in 729 
Endothelial Cells through BECLIN-1 Transcriptional Activation. J Biol Chem 2013;288:859–730 
72. doi:10.1074/jbc.M112.412783 731 
93  Hetz C, Thielen P, Matus S, et al. XBP-1 deficiency in the nervous system protects against 732 
amyotrophic lateral sclerosis by increasing autophagy. Genes Dev 2009;23:2294–306. 733 
doi:10.1101/gad.1830709 734 
94  Avivar-Valderas A, Bobrovnikova-Marjon E, Diehl JA, et al. Regulation of autophagy during 735 
ECM detachment is linked to a selective inhibition of mTORC1 by PERK. Oncogene 736 
2013;32:4932–40. doi:10.1038/onc.2012.512 737 
95  Ji G, Yu N, Xue X, et al. PERK-mediated Autophagy in Osteosarcoma Cells Resists ER Stress-738 
induced Cell Apoptosis. Int J Biol Sci 2015;11:803–12. doi:10.7150/ijbs.11100 739 
96  Jia X-E, Ma K, Xu T, et al. Mutation of kri1l causes definitive hematopoiesis failure via 740 
PERK-dependent excessive autophagy induction. Cell Res 2015;25:946. 741 
97  Kouroku Y, Fujita E, Tanida I, et al. ER stress (PERK/eIF2 [alpha] phosphorylation) mediates 742 
the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. 743 
Cell Death Differ 2007;14:230. 744 
98  Moon H, Kim B, Gwak H, et al. Autophagy and protein kinase RNA-like endoplasmic 745 
reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α) pathway 746 
protect ovarian cancer cells from metformin-induced apoptosis: THE EFFECT OF 747 
METFORMIN ON AUTOPHAGY AND PERK. Mol Carcinog 2016;55:346–56. 748 
doi:10.1002/mc.22284 749 
99  Zhao C, Yin S, Dong Y, et al. Autophagy-dependent EIF2AK3 activation compromises 750 
ursolic acid-induced apoptosis through upregulation of MCL1 in MCF-7 human breast 751 
cancer cells. Autophagy 2013;9:196–207. doi:10.4161/auto.22805 752 
100  Laplante M, Sabatini DM. mTOR Signaling in Growth Control and Disease. Cell 753 
2012;149:274–93. doi:10.1016/j.cell.2012.03.017 754 
101  B’chir W, Maurin A-C, Carraro V, et al. The eIF2α/ATF4 pathway is essential for stress-755 
induced autophagy gene expression. Nucleic Acids Res 2013;41:7683–99. 756 
doi:10.1093/nar/gkt563 757 
102  Avivar-Valderas A, Salas E, Bobrovnikova-Marjon E, et al. PERK Integrates Autophagy and 758 
Oxidative Stress Responses To Promote Survival during Extracellular Matrix Detachment. 759 
Mol Cell Biol 2011;31:3616–29. doi:10.1128/MCB.05164-11 760 
103  Rouschop KMA, van den Beucken T, Dubois L, et al. The unfolded protein response 761 
protects human tumor cells during hypoxia through regulation of the autophagy genes 762 
MAP1LC3B and ATG5. J Clin Invest 2010;120:127–41. doi:10.1172/JCI40027 763 
104  Rzymski T, Milani M, Pike L, et al. Regulation of autophagy by ATF4 in response to severe 764 
hypoxia. Oncogene 2010;29:4424–35. doi:10.1038/onc.2010.191 765 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 37 
105  Gade P, Manjegowda SB, Nallar SC, et al. Regulation of the Death-Associated Protein 766 
Kinase 1 Expression and Autophagy via ATF6 Requires Apoptosis Signal-Regulating Kinase 767 
1. Mol Cell Biol 2014;34:4033–48. doi:10.1128/MCB.00397-14 768 
106  Gade P, Ramachandran G, Maachani UB, et al. An IFN-γ–stimulated ATF6–C/EBP-β–769 
signaling pathway critical for the expression of Death Associated Protein Kinase 1 and 770 
induction of autophagy. Proc Natl Acad Sci U S A 2012;109:10316–21. 771 
doi:10.1073/pnas.1119273109 772 
107  Lopes F, Keita ÅV, Saxena A, et al. ER-stress mobilization of death-associated protein 773 
kinase-1-dependent xenophagy counteracts mitochondria stress-induced epithelial 774 
barrier dysfunction. J Biol Chem 2018;293:3073–87. doi:10.1074/jbc.RA117.000809 775 
108  Appenzeller-Herzog C, Hall MN. Bidirectional crosstalk between endoplasmic reticulum 776 
stress and mTOR signaling. Trends Cell Biol 2012;22:274–82. 777 
doi:10.1016/j.tcb.2012.02.006 778 
109  Yamazaki H, Hiramatsu N, Hayakawa K, et al. Activation of the Akt-NF-kappaB pathway 779 
by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. J 780 
Immunol Baltim Md 1950 2009;183:1480–7. doi:10.4049/jimmunol.0900017 781 
110  Hart LS, Cunningham JT, Datta T, et al. ER stress–mediated autophagy promotes Myc-782 
dependent transformation and tumor growth. J Clin Invest 2012;122:4621–34. 783 
doi:10.1172/JCI62973 784 
111  Li J, Ni M, Lee B, et al. The unfolded protein response regulator GRP78/BiP is required 785 
for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells. 786 
Cell Death Differ 2008;15:1460–71. doi:10.1038/cdd.2008.81 787 
112  Ogata M, Hino S, Saito A, et al. Autophagy is activated for cell survival after endoplasmic 788 
reticulum stress. Mol Cell Biol 2006;26:9220–31. doi:10.1128/mcb.01453-06 789 
113  Wang W, Kang H, Zhao Y, et al. Targeting autophagy sensitizes BRAF-mutant thyroid 790 
cancer to vemurafenib. J Clin Endocrinol Metab 2016;:jc.2016-1999. doi:10.1210/jc.2016-791 
1999 792 
114  Keestra-Gounder AM, Byndloss MX, Seyffert N, et al. NOD1 and NOD2 signalling links ER 793 
stress with inflammation. Nature 2016;532:394–7. doi:10.1038/nature17631 794 
115  Kaneko M, Niinuma Y, Nomura Y. Activation Signal of Nuclear Factor-κB in Response to 795 
Endoplasmic Reticulum Stress is Transduced via IRE1 and Tumor Necrosis Factor 796 
Receptor-Associated Factor 2. Biol Pharm Bull 2003;26:931–5. doi:10.1248/bpb.26.931 797 
116  Urano F, Wang X, Bertolotti A, et al. Coupling of Stress in the ER to Activation of JNK 798 
Protein Kinases by Transmembrane Protein Kinase IRE1. Science 2000;287:664–6. 799 
doi:10.1126/science.287.5453.664 800 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 38 
117  Castillo K, Rojas-Rivera D, Lisbona F, et al. BAX inhibitor-1 regulates autophagy by 801 
controlling the IRE1α branch of the unfolded protein response. EMBO J 2011;30:4465–78. 802 
doi:10.1038/emboj.2011.318 803 
118  Ding W-X, Ni H-M, Gao W, et al. Linking of Autophagy to Ubiquitin-Proteasome System 804 
Is Important for the Regulation of Endoplasmic Reticulum Stress and Cell Viability. Am J 805 
Pathol 2007;171:513–24. doi:10.2353/ajpath.2007.070188 806 
119  Moretti J, Roy S, Bozec D, et al. STING Senses Microbial Viability to Orchestrate Stress-807 
Mediated Autophagy of the Endoplasmic Reticulum. Cell Published Online First: October 808 
2017. doi:10.1016/j.cell.2017.09.034 809 
120  NHS CB. 2013/14 NHS Standard Contract for Colorectal: Complex Inflammatory Bowel 810 
Disease (Adult). 2013.  811 
121  Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the 812 
UK: a single centre retrospective study. Gut 2004;53:1471–8. 813 
doi:10.1136/gut.2004.041616 814 
122  Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn’s disease. 815 
Gut 2012;61:622–9. doi:10.1136/gutjnl-2011-301397 816 
123  Matsuda C, Ito T, Song J, et al. Therapeutic effect of a new immunosuppressive agent, 817 
everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol 818 
2007;148:348–59. doi:10.1111/j.1365-2249.2007.03345.x 819 
124  Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn’s 820 
disease. Gut 2008;57:1294–6. doi:10.1136/gut.2008.157297 821 
125  Dumortier J, Lapalus M-G, Guillaud O, et al. Everolimus for refractory Crohnʼs disease: A 822 
case report: Inflamm Bowel Dis 2008;14:874–7. doi:10.1002/ibd.20395 823 
126  Mutalib M, Borrelli O, Blackstock S, et al. The use of sirolimus (rapamycin) in the 824 
management of refractory inflammatory bowel disease in children. J Crohns Colitis 825 
2014;8:1730–4. doi:10.1016/j.crohns.2014.08.014 826 
127  Reinisch W, Panés J, Lémann M, et al. A multicenter, randomized, double-blind trial of 827 
everolimus versus azathioprine and placebo to maintain steroid-induced remission in 828 
patients with moderate-to-severe active Crohn’s disease. Am J Gastroenterol 829 
2008;103:2284–92. doi:10.1111/j.1572-0241.2008.02024.x 830 
128  Ha J, Kim J. Novel pharmacological modulators of autophagy: an updated patent review 831 
(2012-2015). Expert Opin Ther Pat 2016;26:1273–89. 832 
doi:10.1080/13543776.2016.1217996 833 
129  Galluzzi L, Bravo-San Pedro JM, Levine B, et al. Pharmacological modulation of 834 
autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov 835 
2017;16:487–511. doi:10.1038/nrd.2017.22 836 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 39 
130  Rauthan M, Pilon M. A chemical screen to identify inducers of the mitochondrial 837 
unfolded protein response in C. elegans. Worm 2015;4. 838 
doi:10.1080/21624054.2015.1096490 839 
131  Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2alpha dephosphorylation 840 
protects cells from ER stress. Science 2005;307:935–9. doi:10.1126/science.1101902 841 
132  Okazaki T, Nishio A, Takeo M, et al. Inhibition of the dephosphorylation of eukaryotic 842 
initiation factor 2α ameliorates murine experimental colitis. Digestion 2014;90:167–78. 843 
doi:10.1159/000366414 844 
133  Crespo I, San-Miguel B, Prause C, et al. Glutamine treatment attenuates endoplasmic 845 
reticulum stress and apoptosis in TNBS-induced colitis. PloS One 2012;7:e50407. 846 
doi:10.1371/journal.pone.0050407 847 
134  Yang L, Sha H, Davisson RL, et al. Phenformin activates the unfolded protein response in 848 
an AMP-activated protein kinase (AMPK)-dependent manner. J Biol Chem 849 
2013;288:13631–8. doi:10.1074/jbc.M113.462762 850 
135  Kim H, Moon SY, Kim J-S, et al. Activation of AMP-activated protein kinase inhibits ER 851 
stress and renal fibrosis. Am J Physiol Renal Physiol 2015;308:F226-236. 852 
doi:10.1152/ajprenal.00495.2014 853 
136  Hwang H-J, Jung TW, Ryu JY, et al. Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits 854 
tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 855 
cardiomyocytes. Mol Cell Endocrinol 2014;392:1–7. doi:10.1016/j.mce.2014.04.017 856 
137  Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function 857 
and survival following induction of endoplasmic reticulum stress. Cell Metab 2006;4:391–858 
406. doi:10.1016/j.cmet.2006.10.001 859 
138  Engin F, Hotamisligil GS. Restoring endoplasmic reticulum function by chemical 860 
chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes 861 
Metab 2010;12 Suppl 2:108–15. doi:10.1111/j.1463-1326.2010.01282.x 862 
139  Allaire JM, Crowley SM, Law HT, et al. The Intestinal Epithelium: Central Coordinator of 863 
Mucosal Immunity. Trends Immunol 2018;39:677–96. doi:10.1016/j.it.2018.04.002 864 
140  Boyapati RK, Rossi AG, Satsangi J, et al. Gut mucosal DAMPs in IBD: from mechanisms to 865 
therapeutic implications. Mucosal Immunol 2016;9:567–82. doi:10.1038/mi.2016.14 866 
141  Boyapati RK, Dorward DA, Tamborska A, et al. Mitochondrial DNA Is a Pro-Inflammatory 867 
Damage-Associated Molecular Pattern Released During Active IBD. Inflamm Bowel Dis 868 
Published Online First: 1 May 2018. doi:10.1093/ibd/izy095 869 
142  Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev 870 
Gastroenterol Hepatol 2017;14:9–21. doi:10.1038/nrgastro.2016.169 871 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 40 
143  Nishino K, Nishida A, Inoue R, et al. Analysis of endoscopic brush samples identified 872 
mucosa-associated dysbiosis in inflammatory bowel disease. J Gastroenterol 2018;53:95–873 
106. doi:10.1007/s00535-017-1384-4 874 
144  Wildenberg ME, Koelink PJ, Diederen K, et al. The ATG16L1 risk allele associated with 875 
Crohn’s disease results in a Rac1-dependent defect in dendritic cell migration that is 876 
corrected by thiopurines. Mucosal Immunol 2017;10:352–60. doi:10.1038/mi.2016.65 877 
145  Wildenberg M, Levin A, Vos C, et al. P668 ATG16L1 genotype is associated with response 878 
to anti-TNF in vitro. J Crohns Colitis 2013;7:S279. doi:10.1016/s1873-9946(13)60689-3 879 
146  Levin AD, Koelink PJ, Bloemendaal FM, et al. Autophagy Contributes to the Induction of 880 
Anti-TNF Induced Macrophages. J Crohns Colitis 2016;10:323–9. doi:10.1093/ecco-881 
jcc/jjv174 882 
147  Vos ACW, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab 883 
are involved in healing in vivo and in vitro. Inflamm Bowel Dis 2012;18:401–8. 884 
doi:10.1002/ibd.21818 885 
148  Niess JH, Klaus J, Stephani J, et al. NOD2 polymorphism predicts response to treatment 886 
in Crohn’s disease--first steps to a personalized therapy. Dig Sci 2012;57:879–86. 887 
doi:10.1007/s10620-011-1977-3 888 
149  Chouchana L, Fernández-Ramos AA, Dumont F, et al. Molecular insight into thiopurine 889 
resistance: transcriptomic signature in lymphoblastoid cell lines. Genome Med 2015;7:37. 890 
doi:10.1186/s13073-015-0150-6 891 
150  Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory 892 
bowel disease: the emerging role of epigenetics. Gastroenterology 2013;145:293–308. 893 
doi:10.1053/j.gastro.2013.05.050 894 
151  Kalla R, Ventham NT, Kennedy NA, et al. MicroRNAs: new players in IBD. Gut 895 
2015;64:504–17. doi:10.1136/gutjnl-2014-307891 896 
152  Stevens TW, Matheeuwsen M, Lönnkvist MH, et al. Systematic review: predictive 897 
biomarkers of therapeutic response in inflammatory bowel disease-Personalised 898 
medicine in its infancy. Aliment Pharmacol Ther Published Online First: 30 October 2018. 899 
doi:10.1111/apt.15033 900 
153  Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn’s disease. Gut 901 
2017;:gutjnl-2016-313235. doi:10.1136/gutjnl-2016-313235 902 
 903 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
